Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Adv Biosyst. 2018 Feb 12;2(3):1700123. doi: 10.1002/adbi.201700123

Figure 2.

Figure 2.

Characterization of LXR-40% ApoA1 PA encapsulation. (a) Cryo-TEM shows formation of nanofibers similar to those of PA without encapsulated LXR agonist. (b) LXR-encapsulation by 40% ApoA1 PA resulted in a more β-sheet-like CD spectrum. (c) Tryptophan fluorescence quenching of PA occurred upon encapsulation of LXR agonist. (d) Neither the PA, 4F, LXR, nor the LXR-PA treatments increased percent cholesterol efflux above the control (DMEM) at t = 1 h, but LXR-40% ApoA1 PA did induce significant (*p < 0.05) efflux above the control, 4F, 40% ApoA1 PA, Diluent PA, and LXR at t = 4 h. (e) Effect of PA, peptide, and LXR treatments upon macrophage cell viability in vitro. * indicates p<0.05 vs. LXR-40% ApoA1 PA and LXR.